Vignesh Narasimhan1,2, Kasmira Wilson3,4, Maneka Britto3, Satish Warrier3, A Craig Lynch3, Michael Michael4,5, Jeanne Tie5, Tim Akhurst4, Catherine Mitchell4, Robert Ramsay3,4, Alexander Heriot3,4. 1. Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. vignesh.narasimhan@petermac.org. 2. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. vignesh.narasimhan@petermac.org. 3. Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. 4. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. 5. Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Abstract
BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare clinical presentation, with considerable morbidity and mortality if left untreated. In recent decades, there is growing acceptance for the use of cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC). The aim of this study was to report on our 10-year single-center experience on outcomes following CRS and HIPEC for PMP of appendiceal origin. METHODS: A retrospective analysis of a prospectively maintained database of all patients undergoing CRS and HIPEC for PMP of appendiceal origin over a 10-year period at a statewide referral center was conducted. RESULTS: One hundred and seventy-five cytoreductive procedures were undertaken in 140 patients. The mean patient age was 57.4 years, with a female preponderance (56%). The median PCI was 16, with 73.1% of cases having a complete cytoreduction. Grade III/IV complications occurred in 36 (20.6%) cases, with no mortalities. The median overall and disease-free survival was 100 months and 40 months, respectively, with a 71% 5-year survival. High-grade histology was the main factor identified as an independent predictor of worse overall survival. CONCLUSION: CRS and HIPEC are safe with acceptable rates of morbidity. It can provide very favorable survival in patients with PMP. High-grade histology is a key prognostic factor associated with a worse overall survival.
BACKGROUND:Pseudomyxoma peritonei (PMP) is a rare clinical presentation, with considerable morbidity and mortality if left untreated. In recent decades, there is growing acceptance for the use of cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC). The aim of this study was to report on our 10-year single-center experience on outcomes following CRS and HIPEC for PMP of appendiceal origin. METHODS: A retrospective analysis of a prospectively maintained database of all patients undergoing CRS and HIPEC for PMP of appendiceal origin over a 10-year period at a statewide referral center was conducted. RESULTS: One hundred and seventy-five cytoreductive procedures were undertaken in 140 patients. The mean patient age was 57.4 years, with a female preponderance (56%). The median PCI was 16, with 73.1% of cases having a complete cytoreduction. Grade III/IV complications occurred in 36 (20.6%) cases, with no mortalities. The median overall and disease-free survival was 100 months and 40 months, respectively, with a 71% 5-year survival. High-grade histology was the main factor identified as an independent predictor of worse overall survival. CONCLUSION:CRS and HIPEC are safe with acceptable rates of morbidity. It can provide very favorable survival in patients with PMP. High-grade histology is a key prognostic factor associated with a worse overall survival.
Authors: Patrick L Wagner; Douglas Jones; Anna Aronova; Jinru Shia; Martin R Weiser; Larissa K Temple; Ki Y Chung; Eileen M O'Reilly; David Kelsen; Philip B Paty; Garrett M Nash Journal: Dis Colon Rectum Date: 2012-04 Impact factor: 4.585
Authors: Thomas J Miner; Jinru Shia; David P Jaques; David S Klimstra; Murray F Brennan; Daniel G Coit Journal: Ann Surg Date: 2005-02 Impact factor: 12.969
Authors: Terence C Chua; Brendan J Moran; Paul H Sugarbaker; Edward A Levine; Olivier Glehen; François N Gilly; Dario Baratti; Marcello Deraco; Dominique Elias; Armando Sardi; Winston Liauw; Tristan D Yan; Pedro Barrios; Alberto Gómez Portilla; Ignace H J T de Hingh; Wim P Ceelen; Joerg O Pelz; Pompiliu Piso; Santiago González-Moreno; Kurt Van Der Speeten; David L Morris Journal: J Clin Oncol Date: 2012-05-21 Impact factor: 44.544
Authors: Norman J Carr; Frederic Bibeau; Robert F Bradley; Peggy Dartigues; Roger M Feakins; Kim R Geisinger; Xianyong Gui; Sylvie Isaac; Massimo Milione; Joseph Misdraji; Reetesh K Pai; Manuel Rodriguez-Justo; Leslie H Sobin; Marie-Louise F van Velthuysen; Rhonda K Yantiss Journal: Histopathology Date: 2017-09-19 Impact factor: 5.087